TY - JOUR T1 - Enoximone in status asthmaticus JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00367-2019 VL - 6 IS - 1 SP - 00367-2019 AU - Oscar Schulz AU - Olaf Wiesner AU - Tobias Welte AU - Benjamin-Alexander Bollmann AU - Hendrik Suhling AU - Marius M. Hoeper AU - Markus Busch Y1 - 2020/01/01 UR - http://openres.ersjournals.com/content/6/1/00367-2019.abstract N2 - Bronchial asthma is a chronic disease affecting >300 million people worldwide [1]. The most severe disease manifestation is status asthmaticus, which can be unresponsive to medical therapy. Patients with severe status asthmaticus who require intubation and mechanical ventilation have mortality rates of up to 20% [2]. Airflow obstruction is often so severe that adequate decarboxylation and protective ventilation are not feasible, and extracorporeal membrane oxygenation (ECMO) support is nowadays an established treatment option as a bridge to recovery [3, 4].In a patient with severe status asthmaticus, enoximone, a phosphodiesterase-3 inhibitor, caused immediate bronchodilation http://bit.ly/38UYpUn ER -